Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

Danny Jeyaraju, Sanhita Sengupta, Paulo Maciag, Anna Sureda Balarí, Niels W.C.J. van de Donk, Sagar Lonial, Anita Gandhi, Michael Amatangelo

Blood (2025) 146 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2025-2255

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Blood (2025) 146 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2025-5510

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Blood (2025) 146 (Supplement 1): 64.

https://doi.org/10.1182/blood-2025-64

Published: 2025

Journal Articles

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2262.

https://doi.org/10.1182/blood-2025-2262

Published: 2025

Journal Articles

Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials

Blood (2025) 146 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2025-2260

Published: 2025

Journal Articles

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Blood (2025) 146 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2025-2265

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

Alfredo De La Torre, Claudia Biosca, Felipe Peña-Muñoz, Marta Peña, Julia Ribes-Amoros, Anna Torrent, María Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Nicolás Real, Montserrat Arnan, Eva Gonzalez Barca, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2025-2430

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Anna Sureda Balarí, Abdullah Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas, Brea Lipe, Paula Rodriguez-Otero, Ping Chen, Hongxia Lin, Kexin Jin, Thomas Solomon, Lilia Taningco, Olumoroti Aina, Paulo Maciag, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5810.

https://doi.org/10.1182/blood-2025-5810

Published: 2025

Journal Articles

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Kateryna Filonenko, Marco Picardi, Michal Kurlapski, Livio Trentin, Eva Domingo Domenech, Caterina Patti, Ramon Garcia-Sanz, Javier Nuñez Cespedes, Javier Lopez Jimenez, Agnieszka Giza, Stephane Chauvie, Davide Rossi, Andrea Riccardo Filippi, Maria Pirosa, Marta Bednarek, Anna Sureda Balarí, Alessandro Rambaldi, Andrea Gallamini, Jan Maciej Zaucha

Blood (2025) 146 (Supplement 1): 8243.

https://doi.org/10.1182/blood-2025-8243

Published: 2025

Journal Articles

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2025-3620

Published: 2025

Journal Articles

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Felipe Peña-Muñoz, Fernando Molina, Marta Peña, Julia Ribes-Amoros, Anna Torrent, Maria Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Montserrat Arnan, Eva Gonzalez Barca, Carlota Gudiol, Julia Laporte, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 7711.

https://doi.org/10.1182/blood-2025-7711

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial

Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma

Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only